The Pharmaceutical Market: Egypt

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Executive Summary

THE PHARMACEUTICAL MARKET: EGYPT - REVIEW

On 25th November 2011, Kamal Ahmad el-Ganzouri was appointed head of the Egyptian Salvation Government. According to the Economist Intelligence Unit (EIU), the Supreme Council of the Armed Forces (SCAF) held a lower house parliamentary election between 28th November 2011 and 3rd January 2012. During this third round, more than 14 million people were eligible to vote on the 150 seats in nine governorates. Entering this final round, the Muslim Brotherhood had registered more than 40% of the vote, with its main rival, the Al Nour party, gaining more than 20%. In final results, made public on 21st January 2012, the Brotherhood held a majority of 47% and the Nour Party had 24.3% of seats. Final results are expected in the week commencing 9th January 2012. Elections for the less-powerful upper house of parliament, the Shura Council, began on 29th January 2012, while presidential elections are scheduled for June 2012. As a result, the SCAF is expected to control power until a new president is elected. The EIU adds that the SCAF envisages that the presidential election will take place after the referendum on the new constitution, which would mean that Egypt would continue to be under military control for most of 2012 and perhaps part of 2013.

Providing the political situation stabilises and the economy continues to perform well, the Egyptian pharmaceutical market at retail prices is expected to rise by a double-digit CAGR in US dollar terms between 2011 and 2016. Espicom estimates that the market increased by nearly five times between 1995 and 2010. Nevertheless, per capita consumption is still low. In spite of recent production problems, production is expected to rise as the healthcare system continues its transition towards modernisation. The new pharmaceutical pricing system, if it was fully implemented, would increase the price of new branded and generic pharmaceuticals. Considering opportunities beyond BRIC pharmaceutical markets, Egypt is becoming a very attractive market for multinational pharmaceutical companies focused on emerging markets.

The Egyptian pharmaceutical industry has enjoyed a period of considerable development in recent years. There is a strong domestic production sector and, while the majority is destined for the domestic market and imports play an important role, Egypt has emerged as a leading exporter of pharmaceuticals to Arab, Asian and Eastern European markets. Public production, represented by the state-owned holding company HOLDIPHARMA, accounts for around one-tenth of sales by value and nearly two-tenths by volume. There are a number of leading local private producers, some of them involved in biotechnology, which are strengthening their capabilities; Minapharm Pharmaceuticals, for example, acquired 95.0% of the share capital of the German ProBioGen in June 2010. Some leading multinational producers also manufacture in Egypt, including AstraZeneca, Eli Lilly, GlaxoSmithKline, Hikma, Novartis and Sanofi, in spite of weak IPR standards, particularly in terms of data exclusivity. In 2011, GlaxoSmithKline announced investments of LE500.0 million (US$82.0 million) in Egypt over a five-year period.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Related Pages:

Pharmaceutical Market Turkey

Pharmaceutical Market Israel

More Information...

HIGHLY DETAILED REPORT CONTENT

EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections

MACROENVIRONMENT
Political, economic, legal and demographic analysis

EPIDEMIOLOGY
Disease burden and prevalence

HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce

REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET ANALYSIS
Projections, product development, manufacturing and trade

COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis

DIRECTORY

METHODOLOGY & SOURCES

SHOW LESS READ MORE >

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections

MACROENVIRONMENT
Political, economic, legal and demographic analysis

EPIDEMIOLOGY
Disease burden and prevalence

HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce

REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET ANALYSIS
Projections, product development, manufacturing and trade

COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis

DIRECTORY

METHODOLOGY & SOURCES

- Arab Company for Drug Industries and Medical Appliances (ACDIMA)
- Bristol-Myers Squibb Egypt
- Chemical Industries Development (CID)
- Egyptian International Pharmaceutical Industries Co. (EIPICo)
- El Amriya
- El Nasr Pharmaceutical Chemicals Co.
- GlaxoSmithKline Egypt S.A.E.
- Kahira Pharmaceutical & Chemical Industrial Co.
- Minapharm Company for Pharmaceutical & Chemical Industries
- Misr for Pharmaceutical Industries
- Novartis Pharma S.A.E.
- October Pharma S.A.E.
- Pfizer Egypt S.A.E.
- South Egypt Drug Industry (SEDICO)
- Tenth of Ramadan Co., Pharmaceutical Industries & Diagnostic Reagents
- The Alexandria Co. for Pharmaceuticals and Chemical Industries
- The Arab Drug Company (ADCO)